소아용 백신 시장 : 백신 유형, 질환, 기술, 수명주기 단계, 제형, 최종사용자, 연령층별 - 시장 예측(2026-2032년)

The Pediatric Vaccines Market is projected to grow by USD 79.72 billion at a CAGR of 7.62% by 2032.

Pediatric Vaccines Market Executive Summary

Pediatric vaccines remain one of the highest-impact interventions in global public health, preventing an estimated 3.5 million to 5 million deaths every year, according to the World Health Organization. The market is anchored by routine childhood immunization programs covering diphtheria, tetanus, pertussis, polio, measles, hepatitis B, Haemophilus influenzae type b, pneumococcal disease, rotavirus, human papillomavirus, influenza, and newer vaccines against malaria and respiratory syncytial virus where approved or recommended.

Demand is shaped by birth cohorts, national immunization schedules, public procurement, pediatric disease burden, cold-chain readiness, vaccine confidence, and access to primary care. WHO and UNICEF estimates show global DTP3 coverage at 84% in 2023, still below the pre-pandemic level and leaving millions of children under-immunized. This coverage gap keeps pediatric vaccine investment central to healthcare resilience, especially as measles outbreaks, pertussis resurgences, and climate-linked disease shifts increase the urgency for strong childhood vaccination systems.

For manufacturers, governments, distributors, and healthcare providers, the pediatric vaccines landscape is moving from volume-led supply toward evidence-led, digitally enabled, equity-focused immunization. Competitive advantage increasingly depends on reliable manufacturing, combination vaccine innovation, regional partnerships, pharmacovigilance strength, affordability strategies, and the ability to support last-mile delivery in both high-income and resource-constrained settings.

Transformative Shifts in the Pediatric Vaccines Landscape

The pediatric vaccines landscape is being reshaped by the convergence of disease resurgence, new vaccine platforms, and renewed attention to immunization equity. The pandemic disrupted routine immunization services worldwide, and the recovery remains uneven. WHO and UNICEF reported 14.5 million zero-dose children in 2023, emphasizing that market growth is inseparable from access expansion, catch-up campaigns, and stronger primary healthcare systems.

Combination vaccines are gaining strategic importance because they reduce the number of injections, improve adherence to pediatric schedules, and simplify logistics for providers. At the same time, next-generation technologies, including mRNA, recombinant protein, viral vector, conjugate, and adjuvanted platforms, are expanding the pediatric pipeline. New approvals and recommendations for malaria vaccines and RSV prevention are also broadening the definition of pediatric immunization beyond long-established antigens.

Procurement is also shifting. Governments and pooled purchasing agencies are placing greater emphasis on supply security, local or regional manufacturing, transparent pricing, and diversified sourcing. This is especially relevant for vaccines requiring complex production, such as pneumococcal conjugate vaccines and combination pediatric vaccines. As a result, market leaders are prioritizing capacity expansion, technology transfer, and partnerships with public health institutions to reduce exposure to supply shocks.

Cumulative Impact of Artificial Intelligence on Pediatric Vaccines

Artificial intelligence is becoming a practical enabler across pediatric vaccine discovery, development, manufacturing, safety monitoring, and delivery. In research and development, AI-supported antigen selection, protein structure prediction, immune-response modeling, and clinical trial optimization can shorten learning cycles and help identify vaccine candidates with stronger immunogenicity profiles. These tools are particularly valuable for pathogens with complex immune biology and for pediatric populations where trial design must meet strict safety and ethical standards.

In manufacturing and supply chain operations, AI can improve demand forecasting, batch-quality monitoring, cold-chain risk detection, and inventory allocation. Pediatric vaccines are highly sensitive to stockouts because missed windows in childhood immunization schedules can create long-term immunity gaps. AI-driven forecasting that integrates birth data, historical coverage, disease surveillance, weather patterns, and clinic-level consumption can help ministries of health and suppliers allocate doses more accurately.

AI also strengthens pharmacovigilance and vaccine confidence when used responsibly. Natural language processing can help identify safety signals from adverse-event databases, call centers, and clinical notes, while digital listening tools can detect misinformation trends that may affect parental decisions. However, AI adoption must be governed by transparent validation, privacy protection, bias mitigation, and human clinical oversight to ensure that algorithmic tools support, rather than replace, evidence-based pediatric immunization decisions.

Key Regional Insights Across Pediatric Vaccines

Asia-Pacific represents one of the most influential pediatric vaccine regions because of its large birth cohorts, expanding public immunization budgets, and growing domestic manufacturing base. China and India play central roles in both demand and supply, while Japan, South Korea, and Australia maintain mature immunization programs with strong regulatory oversight. Regional priorities include combination vaccines, pneumococcal and rotavirus coverage, HPV vaccination, Japanese encephalitis prevention in endemic areas, and stronger cold-chain infrastructure across rural and island geographies.

North America is characterized by broad pediatric vaccine availability, established reimbursement pathways, and strong public health guidance from agencies such as the CDC and the Public Health Agency of Canada. The United States Vaccines for Children program remains a major access mechanism for eligible children, while Canada's provincial and territorial programs support routine immunization. The region's key challenge is not product availability but persistent disparities in coverage, parental hesitancy, and localized outbreaks of vaccine-preventable diseases.

Latin America has historically benefited from PAHO's Revolving Fund, which supports pooled vaccine procurement and access across the region. However, several countries experienced declines in routine immunization coverage after the pandemic, increasing the risk of measles, diphtheria, and pertussis outbreaks. Brazil and Mexico remain major demand centers, while regional recovery depends on catch-up campaigns, primary care strengthening, and renewed investment in surveillance.

Europe combines high regulatory standards with uneven vaccine confidence across countries. The European Union supports coordinated disease surveillance and procurement mechanisms, while national immunization technical advisory groups shape pediatric schedules. Recent measles activity reported across the region underscores the need to close subnational coverage gaps and maintain the 95% two-dose measles vaccination threshold recommended for outbreak prevention.

The Middle East shows a dual market structure. GCC countries generally maintain well-funded pediatric immunization programs, advanced healthcare infrastructure, and rapid adoption of selected new vaccines, while conflict-affected settings face service interruptions and cold-chain constraints. Africa remains central to global immunization equity, with Gavi-supported programs, malaria vaccine rollout in eligible countries, and ongoing efforts to reach zero-dose children. The region offers long-term growth potential, but success depends on financing continuity, local manufacturing initiatives, and last-mile delivery capacity.

Key Group Insights for Pediatric Vaccine Growth

ASEAN's pediatric vaccine outlook is shaped by diverse income levels, dense urban populations, remote island communities, and a strong need for resilient cold-chain systems. Countries such as Indonesia, Vietnam, Thailand, Malaysia, and the Philippines continue to prioritize routine immunization recovery, dengue prevention strategies where applicable, and expanded access to HPV, pneumococcal, and rotavirus vaccines. Regional cooperation can improve procurement efficiency, regulatory convergence, and outbreak preparedness.

The GCC represents a high-value pediatric vaccines group due to strong public healthcare investment, high digital health adoption, and government-led prevention strategies. Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman typically maintain comprehensive childhood immunization schedules and are well positioned to adopt advanced vaccines where supported by health technology assessment and national disease burden data.

The European Union is a regulatory and policy anchor for pediatric vaccines, with the European Medicines Agency, ECDC surveillance, and joint procurement experience supporting coordinated action. While immunization schedules remain nationally determined, EU-level cooperation improves safety monitoring, outbreak response, and evidence generation. The group's main priority is sustaining confidence and closing coverage gaps among underserved and mobile populations.

BRICS countries are strategically important because they combine large pediatric populations, expanding healthcare investment, and significant vaccine manufacturing capabilities. China, India, Brazil, Russia, and South Africa influence global supply security, technology transfer, and affordable vaccine access. The G7 remains a major source of vaccine innovation, financing, regulatory leadership, and global health funding, while NATO countries increasingly view vaccine supply chains, biodefense, and health system resilience as part of broader security preparedness.

Key Country Insights in Pediatric Vaccines

The United States remains a leading pediatric vaccines market, supported by CDC recommendations, private insurance coverage, Medicaid, and the Vaccines for Children program, though coverage disparities and hesitancy continue to affect uptake. Canada maintains strong public immunization programs through provincial and territorial delivery, with national guidance supporting schedule consistency. Mexico is focused on restoring routine coverage and strengthening procurement reliability, while Brazil combines a large public immunization system with domestic production capabilities through public health institutes.

In Europe, the United Kingdom has a long-standing national immunization program and strong surveillance infrastructure, while Germany, France, Italy, and Spain represent major markets shaped by national recommendations, reimbursement, and public confidence dynamics. France has strengthened childhood vaccine requirements in recent years, Germany emphasizes Standing Committee on Vaccination guidance, and Italy and Spain continue to address regional coverage variation. Russia maintains domestic vaccine production capacity and a large pediatric population, with demand influenced by national schedule priorities and public procurement.

In Asia-Pacific, China's pediatric vaccine market is supported by a large birth cohort, national immunization planning, and an expanding domestic industry, while India is central to global supply and demand through its Universal Immunization Programme and established production capacity. Japan emphasizes high-quality regulation and schedule-based pediatric prevention, Australia sustains strong coverage through the National Immunisation Program, and South Korea combines advanced healthcare infrastructure with strong public health delivery. Across these countries, growth is tied to combination vaccines, catch-up immunization, HPV expansion, pneumococcal and rotavirus access, and readiness for new pediatric indications.

Actionable Recommendations for Pediatric Vaccine Leaders

Industry leaders should prioritize pediatric vaccine strategies that combine innovation with access. Manufacturers can improve competitiveness by investing in combination vaccines, thermostability improvements, preservative-free presentations where appropriate, and scalable platforms that support rapid response to emerging pediatric threats. Portfolio decisions should be guided by disease burden, national immunization priorities, health economic evidence, and implementation feasibility.

Supply resilience should be treated as a strategic differentiator. Companies and public agencies should diversify suppliers, strengthen regional fill-finish capacity, improve demand forecasting, and maintain transparent allocation plans for constrained products. Partnerships with Gavi, UNICEF, PAHO, national ministries of health, and regional manufacturers can support more predictable supply and broader market access.

Commercial and public health teams should invest in evidence-based vaccine confidence programs. Pediatric vaccination decisions are strongly influenced by healthcare professionals, parents, community leaders, and digital information environments. Clear safety communication, active pharmacovigilance, culturally relevant outreach, and integration with maternal and child health services can improve acceptance and reduce missed opportunities.

Digital transformation should focus on measurable immunization outcomes. AI-enabled forecasting, electronic immunization registries, reminder-recall systems, and cold-chain monitoring can increase coverage when supported by privacy safeguards and workforce training. Leaders should also build market access dossiers that demonstrate real-world effectiveness, budget impact, equity benefits, and long-term reductions in healthcare utilization.

Research Methodology for Pediatric Vaccines Analysis

This executive summary is developed using a structured secondary research methodology focused on verified public health, regulatory, and market intelligence sources. Core inputs include WHO and UNICEF immunization coverage estimates, CDC immunization guidance, ECDC surveillance updates, PAHO procurement and regional immunization resources, Gavi program information, national immunization schedules, World Bank demographic indicators, and public disclosures from health authorities and vaccine developers.

The analysis triangulates disease burden, vaccination coverage, birth cohort dynamics, procurement models, technology trends, policy shifts, and regional access factors. Market interpretation emphasizes data consistency, source credibility, recency, and relevance to pediatric vaccine decision-making. Qualitative insights are assessed against observable indicators such as routine immunization recovery, zero-dose child estimates, outbreak patterns, national program expansion, and regulatory developments.

All conclusions are framed to support executive-level planning for manufacturers, suppliers, healthcare providers, investors, and public health stakeholders. The methodology avoids unsupported projections and prioritizes evidence-backed drivers, constraints, and opportunities that can be monitored through official immunization, surveillance, procurement, and regulatory datasets.

Conclusion: Pediatric Vaccines as a Public Health Growth Priority

The pediatric vaccines market is entering a more complex and strategically important phase. Routine immunization remains foundational, yet the operating environment is being transformed by coverage gaps, disease resurgence, new vaccine technologies, supply security concerns, and the need for stronger last-mile delivery. Stakeholders that align scientific innovation with affordability, trust, and implementation support will be best positioned to create durable public health and commercial value.

Regional and country-level differences will continue to define opportunity. High-income markets will emphasize advanced vaccines, confidence-building, and lifecycle management, while emerging markets will prioritize access, financing, cold-chain expansion, and domestic capacity. Across all settings, the central market imperative is clear: pediatric vaccines must reach every child at the right time, with reliable supply, trusted evidence, and resilient delivery systems.

AI, digital registries, and data-driven procurement can accelerate progress, but they must be deployed with transparent governance and measurable public health outcomes. The next stage of market leadership will belong to organizations that can integrate innovation, operational excellence, and equity into a unified pediatric immunization strategy.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pediatric Vaccines Market, by Vaccine Type

• 7.1. Hexavalent
• 7.2. Monovalent
• 7.3. Pentavalent
• 7.4. Quadrivalent

8. Pediatric Vaccines Market, by Disease

• 8.1. DTP
  • 8.1.1. Diphtheria
  • 8.1.2. Pertussis
  • 8.1.3. Tetanus
• 8.2. Hepatitis B
• 8.3. Hib
• 8.4. Measles
• 8.5. Pneumococcal
• 8.6. Polio
• 8.7. Rotavirus

9. Pediatric Vaccines Market, by Technology

• 9.1. Conjugate
  • 9.1.1. Polysaccharide Conjugate
  • 9.1.2. Protein Conjugate
• 9.2. Inactivated
  • 9.2.1. Toxoid
  • 9.2.2. Viral
• 9.3. Live Attenuated
  • 9.3.1. Bacterial
  • 9.3.2. Viral
• 9.4. Recombinant
  • 9.4.1. Mammalian Cell Culture
  • 9.4.2. Yeast Based
• 9.5. Subunit
  • 9.5.1. Peptide Subunit
  • 9.5.2. Protein Subunit

10. Pediatric Vaccines Market, by Lifecycle Stage

• 10.1. Commercialized
• 10.2. Registration
• 10.3. Phase III
• 10.4. Preclinical And Early Clinical

11. Pediatric Vaccines Market, by Formulation

• 11.1. Liquid
• 11.2. Lyophilized

12. Pediatric Vaccines Market, by End User

• 12.1. Clinics
  • 12.1.1. General Clinics
  • 12.1.2. Specialty Clinics
• 12.2. Hospitals
  • 12.2.1. Private Hospitals
  • 12.2.2. Public Hospitals
• 12.3. Immunization Centers
• 12.4. Pharmacies
  • 12.4.1. Hospital Pharmacies
  • 12.4.2. Retail Pharmacies

13. Pediatric Vaccines Market, by Age Group

• 13.1. Adolescents
• 13.2. Children
• 13.3. Infants
• 13.4. Neonates
• 13.5. Toddlers

14. Pediatric Vaccines Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Pediatric Vaccines Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Pediatric Vaccines Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. AJ Vaccines A/S
• 18.2. AstraZeneca PLC
• 18.3. Bavarian Nordic A/S
• 18.4. Bharat Biotech International Limited
• 18.5. Biological E. Limited
• 18.6. BioNTech SE
• 18.7. CanSino Biologics Inc.
• 18.8. CSL Limited
• 18.9. Daiichi Sankyo Company, Ltd.
• 18.10. Emergent BioSolutions Inc.
• 18.11. EuBiologics Co., Ltd.
• 18.12. GC Biopharma Corp.
• 18.13. GSK plc
• 18.14. Haffkine Bio-Pharmaceutical Corporation Ltd.
• 18.15. Indian Immunologicals Limited
• 18.16. Johnson & Johnson
• 18.17. LG Chem Ltd.
• 18.18. Merck Sharp & Dohme LLC
• 18.19. Mitsubishi Tanabe Pharma Corporation
• 18.20. Moderna, Inc.
• 18.21. Novavax, Inc.
• 18.22. Panacea Biotec Ltd.
• 18.23. Pfizer Inc.
• 18.24. Sanofi S.A.
• 18.25. Serum Institute of India Pvt. Ltd.
• 18.26. Sinovac Biotech Ltd.
• 18.27. SK Bioscience Co., Ltd.
• 18.28. Takeda Pharmaceutical Company Limited
• 18.29. Valneva SE
• 18.30. Xiamen Innovax Biotech Co., Ltd.